| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |